27.01.2014 - Indian drugmaker Ranbaxy Laboratories faces long delays and high costs in launching big-selling generic drugs in the U.S. after products from a fourth plant were banned due to...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)